Ribociclib resistance lasts for several years

The resistance time to Ribociclib (Ribociclib) can vary due to individual differences and other factors, and there is no specific fixed time. The occurrence of drug resistance depends on many factors, including the patient's genotype, tumor characteristics, treatment regimen and other treatments. Some studies suggest that the therapeutic response to rebociclib may diminish over time, but this still needs to be evaluated on a patient-by-patient basis. Sometimes resistance can develop within a few months, sometimes it can take longer, and it can even last for years.

In a clinical trial calledMONALEESA-2, women who received the CDK4/6 inhibitor rebociclib and the hormone-blocking drug letrozole (Femara) as initial treatment for advanced cancer lived about a year longer overall than women who received letrozole alone. Median overall survival was nearly 64 months for patients who received both drugs and more than 51 months for those who received letrozole alone. Importantly, drug resistance is not a static process and may change as treatment strategies are adjusted. Physicians usually closely monitor patients' efficacy and resistance and make appropriate treatment adjustments as needed.

The original drug Riboxil has been launched in China, but due to its short time on the market, its price and purchase methods are not yet known, and it has not yet been included in the scope of medical insurance. The price of the European version of Riboxil's original drug, 200mg*21 tablets, sold overseas may be more than RMB 20,000 per box, while the Indian version of Riboxil's original drug, 200mg*21 tablets, may be priced around RMB 3,000 per box (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same. There are currently no generic versions of Riboxil produced and marketed.